Specialty drug growth is accelerating, but billing infrastructure has not kept pace. High-cost therapies now represent a growing share of total drug spend and pipeline volume. At the same time, medical benefit claims, prior authorizations, payer policy changes and 340B…
Presented by:
- David Pope, PharmD, Chief Pharmacy Officer XiFin, Inc.
- Mike Fauver, Vice President, Enterprise Solutions XiFin, Inc.
- Heather Agostinelli, Vice President, Head of Specialty RCM XiFin, Inc.
